We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection

This study has been terminated.
(Five immune related serious adverse events)
Sponsor:
ClinicalTrials.gov Identifier:
NCT01829971
First Posted: April 11, 2013
Last Update Posted: September 27, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Cancer Prevention Research Institute of Texas
Information provided by (Responsible Party):
Mirna Therapeutics, Inc.
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: May 2017
  Estimated Primary Completion Date: March 2017 (Final data collection date for primary outcome measure)